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A BS TR AC T
BACKGROUND
Studies in animals and in vitro and phase 2 studies in humans suggest that statins 
may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). 
This study tested the hypothesis that treatment with simvastatin would improve 
clinical outcomes in patients with ARDS.
METHODS
In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) 
patients with an onset of ARDS within the previous 48 hours to receive enteral 
simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The 
primary outcome was the number of ventilator-free days to day 28. Secondary out-
comes included the number of days free of nonpulmonary organ failure to day 28, 
mortality at 28 days, and safety.
RESULTS
The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 
to placebo. The groups were well matched with respect to demographic and base-
line physiological variables. There was no significant difference between the study 
groups in the mean (±SD) number of ventilator-free days (12.6±9.9 with simvastatin 
and 11.5±10.4 with placebo, P = 0.21) or days free of nonpulmonary organ failure 
(19.4±11.1 and 17.8±11.7, respectively; P = 0.11) or in mortality at 28 days (22.0% and 
26.8%, respectively; P = 0.23). There was no significant difference between the two 
groups in the incidence of serious adverse events related to the study drug.
CONCLUSIONS
Simvastatin therapy, although safe and associated with minimal adverse effects, did 
not improve clinical outcomes in patients with ARDS. (Funded by the U.K. National 
Institute for Health Research Efficacy and Mechanism Evaluation Programme and 
others; HARP-2 Current Controlled Trials number, ISRCTN88244364.)
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The acute respiratory distress syn-drome (ARDS) is a common, devastating clinical syndrome characterized by life-
threatening respiratory failure requiring mechani-
cal ventilation and by multiple organ failure. In 
ARDS there is an uncontrolled inflammatory re-
sponse that results in alveolar damage, with the 
exudation of protein-rich pulmonary-edema fluid 
in the alveolar space that results in respiratory 
failure.1
The inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase with statins 
has been shown to modify a number of the un-
derlying mechanisms implicated in the develop-
ment of ARDS.2 Statins decrease inflammation 
and histologic evidence of lung injury in murine 
models of ARDS.3 Simvastatin reduced pulmonary 
and systemic inflammatory responses in a human 
model of ARDS induced by lipopolysaccharide 
inhalation.4 In addition, in a small, single-center, 
randomized, placebo-controlled study involving 
patients with acute lung injury, simvastatin ame-
liorated nonpulmonary organ dysfunction and was 
safe.5 That phase 2 study was not designed or 
powered to show an effect of simvastatin on 
clinical outcomes. The aim of this trial was to 
test the hypothesis that treatment with enteral 
simvastatin at a dose of 80 mg daily would im-
prove clinical outcomes in patients with ARDS, 
regardless of the cause.
ME THODS
STUDY DESIGN
Patients were adults recruited from general in-
tensive care units (ICUs) in 40 hospitals in the 
United Kingdom and Ireland (see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). The study was approved 
by a national research ethics committee and by the 
research governance department at each study site 
in the United Kingdom and by the institutional 
research ethics committee at each study site in 
Ireland. The Northern Ireland Clinical Trials Unit 
coordinated the overall trial, with support from 
the Health Research Board Galway Clinical Re-
search Facility for centers in Ireland. All the pa-
tients or their representatives provided written 
informed consent. Simvastatin was purchased for 
use in the study. The funders had no role in the 
study design, data acquisition, data analysis, or 
manuscript preparation.
The study design has been published previ-
ously,6 and the study protocol, including the 
statistical analysis plan, is available at NEJM.org. 
The first three authors designed the study, and 
all the authors made a substantial contribution to 
the development of the study protocol. The first 
author wrote the first draft of the manuscript, 
and all the authors critically reviewed it for im-
portant intellectual content. All the authors ap-
proved the manuscript and made the decision to 
submit it for publication. The first and second 
authors vouch for the integrity, accuracy, and com-
pleteness of the data and analyses and for the 
fidelity of the study to the protocol.
PATIENTS
Patients were eligible if they were intubated and 
mechanically ventilated and were within 48 hours 
after the onset of ARDS as defined by a ratio of the 
partial pressure of arterial oxygen (Pao2) to the 
fraction of inspired oxygen (Fio2) of 300 mm Hg 
or less, if bilateral pulmonary infiltrates consis-
tent with pulmonary edema were present on 
chest radiography, and if there was no evidence 
of left atrial hypertension.7 The main exclusion 
criteria are listed in Figure 1, and the full list is 
provided in the study protocol. The study proto-
col was amended to permit the enrollment of 
patients receiving macrolides 9 months into the 
study and to increase the eligibility criterion re-
garding the level of alanine aminotransferase 
or aspartate aminotransferase from more than 
5 times the upper limit of the normal range 
to 8 times the upper limit of the normal range 
15 months into the study.
STUDY MEDICATION
Randomization was performed with an automat-
ed, centralized, 24-hour randomization service. 
Patients were randomly assigned to the study 
groups in a 1:1 ratio with the use of permuted 
blocks and stratification according to study site 
and vasopressor requirement (yes vs. no).
Patients received once-daily simvastatin (at a 
dose of 80 mg) or identical placebo tablets enter-
ally for up to 28 days. The first dose of the study 
drug was administered as soon as possible, ideally 
within 4 hours after randomization, and subse-
quent doses were given each morning starting on 
the following calendar day.
The study drug was continued until day 28, 
discharge from critical care (ICU or high-depen-
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dency unit, in which patients requiring organ sup-
port but not intensive care or invasive mechanical 
ventilation are treated), death, discontinuation 
of active medical treatment, development of a 
clinical condition requiring immediate treatment 
with a statin, or withdrawal of the patient from 
the study. The study drug was stopped on safety 
grounds if the attending clinician determined 
that this was required, if the level of creatine 
kinase was more than 10 times the upper limit 
of the normal range, or if the level of alanine 
aminotransferase or aspartate aminotransferase 
was more than 8 times the upper limit of the 
normal range.
DATA COLLECTION AND PROCEDURES
At enrollment, each patient’s demographic char-
acteristics, ventilatory and physiological vari-
ables, and Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score at the time of 
admission were recorded. The cause of ARDS 
was identified by the treating clinician. For each 
day in the ICU, ventilatory and physiological vari-
ables as well as data regarding organ support, 
 540 Underwent randomization
5926 Patients were assessed for eligibility
5386 Were excluded
9 Were <16 yr of age
312 Were not intubated and ventilated
719 Were assessed >48 hr after onset of ARDS
15 Were known to be pregnant
194 Had an elevated creatine kinase level
342 Had an elevated aminotransferase level
340 Had an interaction with concomitant drug
235 Had severe renal impairment and were not 
receiving renal-replacement therapy
223 Had severe liver disease
1803 Had received statins within the previous 2 wk
75 Required a statin for a proven indication
117 Had a contraindication to enteral drug
administration
103 Were enrolled in another drug trial
309 Were having treatment imminently withdrawn
197 Declined consent
836 Had other reasons
259 Were assigned to receive simvastatin
254 Received simvastatin
5 Did not receive simvastatin
2 Were receiving a statin
1 Had elevated aminotransferase 
level
2 Were unable to have nasogastric
tube inserted
281 Were assigned to receive placebo
278 Received placebo
3 Did not receive placebo
1 Had elevated creatine kinase level
1 Withdrew consent
1 Had other reason
1 Was lost to follow-up 2 Withdrew consent
258 Were included in primary analysis 279 Were included in primary analysis
Figure 1. Screening, Randomization, and Follow-up of the Study Participants.
There may have been more than one reason for exclusion of a patient from the study. Severe liver disease was de-
fined as a Child–Pugh score of more than 12 (on a scale from 5 to 15, with higher scores indicating more severe 
liver disease).
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which were based on the Critical Care Minimum 
Data Set of the United Kingdom,8 were recorded. 
Vital status at 28 days was recorded, but for pa-
tients who died, the cause of death was not re-
corded.
Participating ICUs were encouraged to use low-
tidal-volume ventilation at 6 to 8 ml per kilo-
gram of predicted body weight and to maintain 
a plateau pressure of less than 30 cm of water,9 
but no specific ventilator-management scheme was 
promulgated. All other treatment decisions were 
made by the patients’ physicians.
OUTCOME MEASURES
The primary outcome measure was the number 
of ventilator-free days to day 28, which was de-
fined as the number of days from the time of 
initiating unassisted breathing to day 28 after 
randomization.6 A detailed definition of ventila-
tor-free days is provided in the study protocol. 
Secondary outcomes included the change in the 
oxygenation index and the Sequential Organ Fail-
ure Assessment (SOFA) score10 up to day 28, the 
number of days free of nonpulmonary organ fail-
ure to day 28, death from any cause within 28 
days after randomization, death before discharge 
from critical care or the hospital, and safety. 
Scores on the SOFA range from 0 to 24, with high-
er scores indicating more severe disease. The 
score is calculated from the sum of six individual 
organ scores (each on a scale from 0 to 4), for the 
respiratory, cardiovascular, hepatic, coagulation, 
renal, and neurologic systems. Individual organ 
scores of less than 2 were used to indicate the ab-
sence of clinically significant organ dysfunction.
Additional secondary outcomes are listed in 
the study protocol. The plasma C-reactive protein 
level was measured by means of an immunotur-
bidimetric assay (Randox Testing Services) in 
blood obtained at baseline and on days 3 and 7.
STATISTICAL ANALYSIS
Sample-size assumptions were based on previ-
ously published data.5,9 Assuming a mean (±SD) 
number of ventilator-free days of 12.7±10.6, we 
estimated that a sample of 524 patients would 
need to be enrolled in order for the study to have 
80% power, at a two-tailed significance level of 
0.05, to detect a mean between-group difference 
of 2.6 ventilator-free days. On the basis of data 
from the Pulmonary Artery Catheters in Manage-
ment of Patients in Intensive Care (PAC-Man) trial, 
we estimated that the study-withdrawal rate 
would be 3%,11 and we therefore calculated that 
the study required a total of 540 patients.
Analyses were performed on an intention-to-
treat basis. Because ventilator-free days and days 
free of nonpulmonary organ failure are known 
to have a bimodal distribution, the data were ini-
tially analyzed by means of Student’s t-test, with 
between-group differences presented as means 
and 95% confidence intervals. A secondary analy-
sis of these outcome measures involving a boot-
strapped t-test was also conducted to support 
the results of the primary analysis, as detailed in 
the statistical analysis plan (see the study proto-
col). For binary outcome measures, risk ratios 
and associated 95% confidence intervals were 
calculated. Time-to-event data are presented as 
Kaplan–Meier plots. The hazard ratios were cal-
culated and the log-rank chi-square test was used 
to compare survival in the two study groups. All 
hazard ratios are presented with a two-sided 
95% confidence interval. All reported P values are 
two-sided. Prespecified subgroup analyses were 
performed to determine whether the treatment 
effect was modified by age, vasopressor require-
ment, presence or absence of sepsis, or baseline 
C-reactive protein level. We used a statistical test 
of interaction for the subgroup analyses, and the 
results are reported with 99% confidence intervals.
R ESULT S
PARTICIPANTS
Patients were recruited from December 21, 2010, 
until March 13, 2014. Of the 5926 patients who 
were assessed for eligibility, 540 (9%) underwent 
randomization. A total of 8 patients who did not 
fulfill the eligibility criteria underwent random-
ization in error, with 4 assigned to each group; 
these patients were included in the analysis. A to-
tal of 5 patients in the simvastatin group and 3 in 
the placebo group did not receive the assigned 
study drug. One patient, in the simvastatin group, 
was lost to follow-up. No data on the primary 
outcome were available for this patient in the sim-
vastatin group and for 2 patients in the placebo 
group (Fig. 1).
The baseline characteristics of the patients at 
randomization were similar in the two study 
groups, except for a small but significant differ-
ence in the Pao2:Fio2 ratio, which was lower in 
the simvastatin group than in the placebo group 
The New England Journal of Medicine 
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(Table 1). The main causes of ARDS were pneu-
monia and sepsis. At day 3, the tidal volume in 
the simvastatin group did not differ significantly 
from that in the placebo group; the mean differ-
ence was 0.05 ml per kilogram of predicted body 
weight (95% confidence interval [CI], −0.61 to 
0.71; P = 0.89).
Patients received the study drug for a mean of 
10.2±7.1 days in the simvastatin group and 
11.0±7.9 days in the placebo group (P = 0.23). The 
most common reasons for discontinuation of the 
study drug were discharge from critical care, 
death, and an adverse event that was considered 
to be related to the study drug. A total of 5 patients 
assigned to simvastatin and 3 assigned to placebo 
received treatment with nontrial statins (Table S1 
in the Supplementary Appendix).
OUTCOMES
The number of ventilator-free days did not differ 
significantly between the two study groups 
(12.6±9.9 days with simvastatin and 11.5±10.4 days 
with placebo; mean difference, 1.1 days [95% CI, 
−0.6 to 2.8]; P = 0.21). There was also no signifi-
cant between-group difference in the number of 
ventilator-free days after adjustment for the base-
line Pao2:Fio2 ratio (mean difference, 1.4 days 
[95% CI, −0.3 to 3.2]; P = 0.10).
The change from baseline to day 28 in the 
oxygenation index did not differ significantly 
between the two groups (Tables S2 and S3 in the 
Supplementary Appendix), nor did the SOFA 
score (Table S2 in the Supplementary Appendix). 
There were no significant differences in the 
number of days free of nonpulmonary organ 
failure or in mortality at 28 days. Mortality at 
ICU discharge or hospital discharge was also not 
significantly different between the two groups 
(Table 2). Among survivors, the mean duration 
of the ICU stay was 13.9±14.4 days in the simva-
statin group and 14.4±13.3 days in the placebo 
group (mean difference, −0.5 days [95% CI, −3.2 
to 2.2]; P = 0.71); the mean duration of the hos-
pital stay was 37.7±64.5 days and 35.4±31.1 days, 
respectively (mean difference, 2.3 days [95% CI, 
−8.0 to 12.6]; P = 0.66). From randomization to 
day 28, there were no significant differences be-
tween the two groups in the probability of breath-
ing without assistance or the probability of sur-
vival (Fig. 2).
Subgroup analyses did not suggest that the 
effects of simvastatin were modified by any of the 
variables investigated. There was no significant 
interaction between treatment and age (P = 0.62), 
vasopressor requirement (P = 0.17), presence or 
absence of sepsis (P = 0.50), or baseline C-reac-
tive protein level (P = 0.77) (Table S4 in the Sup-
plementary Appendix).
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Simvastatin
(N = 259)
Placebo
(N = 280)
Age — yr 53.2±16.1 54.4±16.7
Male sex — no. (%) 137 (52.9) 170 (60.7)
Sepsis — no. (%) 189 (73.0) 218 (77.9)
Cause of ARDS — no. (%)†
Smoke or toxin inhalation 1 (0.4) 2 (0.7)
Gastric-content aspiration 21 (8.1) 29 (10.4)
Thoracic trauma 22 (8.5) 10 (3.6)
Pneumonia 161 (62.2) 154 (55.0)
Sepsis 106 (40.9) 118 (42.1)
Pancreatitis 5 (1.9) 17 (6.1)
Nonthoracic trauma 4 (1.5) 8 (2.9)
Other 30 (11.6) 36 (12.9)
APACHE II score‡ 19.4±6.9 18.3±6.2
SOFA score§ 8.5±3.2 8.8±2.9
Vasopressor-dependent — no. (%) 169 (65.3) 187 (66.8)
Lowest mean arterial pressure —  
mm Hg
65.4±9.3 64.9±8.4
Inspiratory plateau pressure —  
cm of water
23.6±6.07 23.6±6.03
Tidal volume — ml/kg of predicted body 
weight¶
8.1±2.8 8.1±2.6
Pao2:Fio2 — mm Hg 123.0±54.8 132.4±55.4
Oxygenation index — cm of water/mm Hg 15.0±11.6 14.9±11.9
Alanine aminotransferase — U/liter 45.5±47.1 45.8±43.2
Aspartate aminotransferase — U/liter 59.9±49.4 65.3±63.9
Creatine kinase — U/liter 327.2±499.3 298.3±487.7
* Plus–minus values are means ±SD. There were no significant differences in 
baseline characteristics between the study groups except for the ratio of par-
tial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) 
(P = 0.049). For one patient who had been randomly assigned to the placebo 
group, baseline data were not available because consent was withdrawn, in-
cluding permission to use the data collected to the point of study withdrawal. 
ºARDS denotes acute respiratory distress syndrome.
† Patients may have had more than one cause of ARDS identified.
‡ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II 
scale range from 0 to 71, with higher scores indicating more severe disease.
§  Scores on the Sequential Organ Failure Assessment (SOFA) scale range from 
0 to 24, with higher scores indicating more severe disease.10
¶ The predicted body weight was calculated as 2.3 kg for each inch of height 
above 60 in. (152 cm) added to a base weight of 50.0 kg for men or 45.5 kg 
for women.
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There were no significant differences between 
the simvastatin and placebo groups in the plas-
ma C-reactive protein level at baseline, at day 3, 
or at day 7 (Table S6 in the Supplementary Ap-
pendix). There was also no significant between-
group difference in the change in the C-reactive 
protein level from baseline to day 7 (Table S5 in 
the Supplementary Appendix).
SAFETY
Overall, adverse events related to the study drug 
were significantly more common in the simva-
statin group than in the placebo group. The ma-
jority of the adverse events were related to elevat-
ed creatine kinase and hepatic aminotransferase 
levels. The numbers of serious adverse events 
(other than those reported as trial outcomes, 
such as death) were similar in the two groups 
(Table S7 in the Supplementary Appendix). There 
was no significant between-group difference in 
the proportion of patients with nonpulmonary 
organ dysfunction, as measured by a SOFA score 
of less than 2 for each organ (Table S8 in the Sup-
plementary Appendix).
DISCUSSION
In this large, multicenter, double-blind, random-
ized, placebo-controlled clinical trial involving 
patients with ARDS, simvastatin, as compared 
with placebo, did not improve clinical outcomes. 
Simvastatin was associated with an increase in 
Table 2. Main Clinical Outcomes.*
Variable Simvastatin Placebo Student’s t-Test Bootstrapped t-Test
Difference or 
Risk Ratio
(95% CI) P Value
Difference
(95% CI) P Value
Ventilator-free days, randomization  
to day 28†
No. of patients in analysis 258 279
No. of days (95% CI) 12.6±9.9
(11.3 to 13.8)
11.5±10.4
(10.2 to 12.7)
1.1
(−0.6 to 2.8)‡
0.21 1.1
(−0.7 to 2.8)
0.22
Days free of nonpulmonary organ  
failure, randomization  
to day 28§
No. of patients in analysis 257 279
No. of days (95% CI) 19.4±11.1
(18.0 to 20.8)
17.8±11.7
(16.4 to 19.2)
1.6
(−0.4 to 3.5)‡
0.11 1.6
(−0.3 to 3.5)
0.10
Death from any cause
No. of patients in analysis 259 280
Randomization to day 28 —  
no. (% [95% CI])
57  
(22.0 [17.0 to 27.1])
75  
(26.8 [(21.6 to 32.0])
0.8 
(0.6 to 1.1)¶
0.23 — —
Before discharge from critical care 
— no. (% [95% CI])‖
56  
(21.6 [16.6 to 26.6])
70  
(25.0 [19.9 to 30.0])
0.9 
(0.6 to 1.2)¶
0.36 — —
Before discharge from hospital — 
no. (% [95% CI])
67 
(25.9 [20.5 to 31.2])
90 
 (32.1 [26.7 to 37.6])
0.8 
(0.6 to 1.1)¶
0.13 — —
* Plus–minus values are means ±SD. 
† Ventilator-free days were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization (see 
the study protocol). Patients who died before day 28 were assigned 0 ventilator-free days.
‡ The data show the difference in the number of days.
§  The definition of days free of nonpulmonary organ failure is provided in the study protocol. Patients who died before day 28 were assigned  
0 days free of nonpulmonary organ failure. Organs were considered to be failure-free after patients were discharged from the intensive care 
unit (ICU).
¶ The data show the risk ratio.
‖ Critical care was defined as care in the ICU or the high-dependency unit, in which patients requiring organ support but not intensive care or 
invasive mechanical ventilation are treated.
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adverse events; however, there was no increase in 
serious adverse events. The recent Statins for 
Acutely Injured Lungs from Sepsis (SAILS) study, 
which involved patients with sepsis-associated 
ARDS, showed that rosuvastatin did not improve 
clinical outcomes, as compared with placebo, 
and was associated with fewer days free of renal 
and hepatic failure.12 The population in our study 
was not limited to patients with sepsis-associated 
ARDS, and therefore, taken together, these data 
show little value in the routine use of statins in 
ARDS, regardless of the cause.
We used simvastatin at a dose of 80 mg on 
the basis of our previous data from clinical stud-
ies,4,5 in which simvastatin improved surrogate 
outcomes and biologic mechanisms implicated 
in ARDS. The data from our current study and 
the SAILS trial show that neither a lipophilic 
statin (simvastatin) nor a hydrophilic statin (ro-
suvastatin) is effective in the treatment of ARDS. 
The high dose of simvastatin (80 mg) used in 
this trial was selected on the basis of our pilot 
data5 as well as preclinical data3 and observa-
tional studies.13,14 Although we did not measure 
simvastatin concentrations, it is likely that an 
adequate simvastatin concentration was achieved, 
for several reasons. A prior study involving criti-
cally ill patients showed that simvastatin at a 
daily dose of 80 mg produced systemic drug con-
centrations that were in the high therapeutic 
range.15 Furthermore, patients received simva-
statin for a mean of 10 days. Finally, the increased 
incidence of expected statin-related adverse events 
suggests that sufficient simvastatin concentra-
tions were achieved. The lack of an effect on the 
plasma C-reactive protein level suggests that 
statins cannot modulate inflammation sufficient-
ly to provide a beneficial clinical effect in ARDS. 
It is possible that HMG-CoA reductase is already 
substantially inhibited, as reflected by the low 
cholesterol levels seen in critically ill patients.16
Although the incidence of treatment-related 
adverse events was higher in the simvastatin 
group than in the placebo group, the number of 
serious adverse events was similar in the two 
groups. The finding that the proportion of pa-
tients with no organ dysfunction, as measured 
by the SOFA score, was similar in the two groups 
over the course of the study is reassuring. The 
absence of serious harm with simvastatin in this 
Pr
ob
ab
ili
ty
 o
f S
ur
vi
va
l
1.0
0.8
0.9
0.7
0.6
0.4
0.3
0.1
0.5
0.2
0.0
0 7 14 21 28
Days
Hazard ratio, 1.25 (95% CI, 0.88–1.76)
P=0.20
No. at Risk
Simvastatin
Placebo
259
280
238
250
217
231
208
220
202
205
Placebo
Simvastatin
B Survival
Placebo
Simvastatin
Pr
ob
ab
ili
ty
 o
f U
na
ss
is
te
d 
B
re
at
hi
ng
1.0
0.8
0.9
0.7
0.6
0.4
0.3
0.1
0.5
0.2
0.0
0 7 14 21 28
Days
Hazard ratio, 0.84 (95% CI, 0.68–1.03)
P=0.09
No. at Risk
Simvastatin
Placebo
258
279
166
178
87
102
43
60
19
33
A Unassisted Breathing
Figure 2. Probabilities of Survival and Breathing without Assistance  
from Randomization to Day 28, According to Whether Patients Received 
Simvastatin or Placebo.
Data regarding the primary outcome of unassisted breathing to day 28 
were available for 258 patients in the simvastatin group and for 279 in the 
placebo group (Panel A). Data regarding survival at 28 days were available 
for 1 additional patient in each study group (Panel B): in the simvastatin 
group, we were able to determine survival status for 1 patient although we 
did not have primary-outcome data; and in the placebo group, 1 patient 
who withdrew from the study allowed the use of limited additional data in-
cluding survival to be collected and used.
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population provides reassurance with regard to 
the safety of statins being used for other proven 
indications in patients with ARDS.
We recruited a heterogeneous cohort of pa-
tients with ARDS due to any cause to ensure that 
our findings would be generalizable. Recent data 
have suggested that it may be possible to iden-
tify specific phenotypes within ARDS.17 Future 
studies may identify a subpopulation of patients 
with ARDS who might have a greater response 
to simvastatin than was observed in our study.
Although we recommended best practice for 
the treatment of ARDS, including lung-protective 
ventilation, we did not record, in detail, all the 
aspects of clinical management. At randomiza-
tion, the mean tidal volume was 8.1 ml per kilo-
gram of predicted body weight, and it is possible 
that this level of tidal volume confounded the po-
tential effects of simvastatin. However, this situ-
ation is unlikely, given the similar absence of 
benefit with rosuvastatin in the SAILS study, in 
which the mean tidal volumes were 6.6 and 6.8 ml 
per kilogram of predicted body weight in the two 
study groups.12 Our data on tidal volume and pla-
teau pressure are consistent with those observed in 
other clinical trials in critical care in which ventila-
tion was not strictly defined in the protocol.18
Despite promising findings in early-phase 
clinical trials of statins for the treatment of 
ARDS, these findings have not been translated 
into improvements in patient-centered outcomes 
in large clinical trials. A recent randomized, con-
trolled trial involving patients with ventilator-
associated pneumonia showed that simvastatin 
did not improve clinical outcomes.19 Data on ef-
ficacy that are based on surrogate outcomes must 
be considered with caution, given the absence of 
a clear correlation between surrogate and pa-
tient-centered outcomes. Surrogate outcomes that 
more closely track patient outcomes need to be 
identified.
In conclusion, our study showed that simva-
statin, as compared with placebo, did not increase 
the number of ventilator-free days or improve 
other clinical outcomes in patients with ARDS, 
although it had an acceptable safety profile. These 
results do not support the use of simvastatin in the 
management of ARDS.
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